Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia.
Mannelli F, Piccini M, Bencini S, Gianfaldoni G, Peruzzi B, Caporale R, Scappini B, Fasano L, Quinti E, Ciolli G, Pasquini A, Crupi F, Pilerci S, Pancani F, Signori L, Tarantino D, Maccari C, Paradiso V, Annunziato F, Guglielmelli P, Vannucchi AM. Mannelli F, et al. Among authors: scappini b. Haematologica. 2024 Jan 1;109(1):60-71. doi: 10.3324/haematol.2023.283196. Haematologica. 2024. PMID: 37345475 Free PMC article.
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting.
Ciolli G, Piccini M, Mannelli F, Gianfaldoni G, Scappini B, Fasano L, Crupi F, Quinti E, Pasquini A, Caroprese J, Rotunno G, Pancani F, Signori L, Maccari C, Vanderwert FI, Guglielmelli P, Vannucchi AM. Ciolli G, et al. Among authors: scappini b. Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285934. Online ahead of print. Haematologica. 2024. PMID: 39234864 Free article.
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
Fracchiolla NS, Sciumè M, Papayannidis C, Vitale A, Chiaretti S, Annunziata M, Giglio F, Salutari P, Forghieri F, Lazzarotto D, Lunghi M, Imovilli A, Scappini B, Bonifacio M, Dargenio M, Gurrieri C, Todisco E, Defina M, Del Principe MI, Zappasodi P, Cerrano M, Santoro L, Tagliaferri E, Barozzi E, De Roberto P, Canzi M, Buzzatti E, Sartor C, Passamonti F, Foà R, Curti A. Fracchiolla NS, et al. Among authors: scappini b. Cancers (Basel). 2023 Sep 19;15(18):4623. doi: 10.3390/cancers15184623. Cancers (Basel). 2023. PMID: 37760592 Free PMC article.
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
Dargenio M, Bonifacio M, Chiaretti S, Vitale A, Fracchiolla NS, Papayannidis C, Giglio F, Salutari P, Audisio E, Scappini B, Zappasodi P, Defina M, Forghieri F, Scattolin AM, Todisco E, Lunghi M, Guolo F, Del Principe MI, Annunziata M, Lazzarotto D, Cedrone M, Pasciolla C, Imovilli A, Tanasi I, Trappolini S, Cerrano M, La Starza R, Krampera M, Di Renzo N, Candoni A, Pizzolo G, Ferrara F, Foà R. Dargenio M, et al. Among authors: scappini b. Br J Haematol. 2023 Feb;200(4):440-450. doi: 10.1111/bjh.18537. Epub 2022 Nov 6. Br J Haematol. 2023. PMID: 36335916 Free PMC article.
Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahmé R, Bertoli S, Fianchi L, Micol JB, Gottardi M, Peterlin P, Galimberti S, Thomas X, Rizzuto G, Legrand O, Rondoni M, Raffoux E, Bertani G, Caulier AL, Dargenio M, Bonmati C, Billio A, Lejeune C, Scappini B, Pigneux A, Zappasodi P, Récher C, Grimaldi F, Adès L, Lemoli RM. Cluzeau T, et al. Among authors: scappini b. Blood Adv. 2024 Oct 25:bloodadvances.2024014279. doi: 10.1182/bloodadvances.2024014279. Online ahead of print. Blood Adv. 2024. PMID: 39454204
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study.
Gorini F, Santoro M, Pierini A, Mezzasalma L, Baldacci S, Bargagli E, Boncristiano A, Brunetto MR, Cameli P, Cappelli F, Castaman G, Coco B, Donati MA, Guerrini R, Linari S, Murro V, Olivotto I, Parronchi P, Pochiero F, Rossi O, Scappini B, Sodi A, Vannucchi AM, Coi A. Gorini F, et al. Among authors: scappini b. Front Pharmacol. 2022 May 16;13:869842. doi: 10.3389/fphar.2022.869842. eCollection 2022. Front Pharmacol. 2022. PMID: 35652051 Free PMC article.
Off-label caplacizumab as add-on therapy in a 9-year-old boy with refractory aTTP.
Veltroni M, Pegoraro F, Scappini B, Brugnolo F, Allegro E, Ermini S, Tondo A, Fotzi I, Bambi F, Favre C. Veltroni M, et al. Among authors: scappini b. Ann Hematol. 2022 Jun;101(6):1369-1371. doi: 10.1007/s00277-021-04740-4. Epub 2021 Dec 21. Ann Hematol. 2022. PMID: 34932149 Free PMC article. No abstract available.
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.
Castagnetti F, Binotto G, Capodanno I, Billio A, Calistri E, Cavazzini F, Crugnola M, Gozzini A, Gugliotta G, Krampera M, Lucchesi A, Merli A, Miggiano MC, Minotto C, Poggiaspalla M, Salvucci M, Scappini B, Tiribelli M, Trabacchi E, Rosti G, Galimberti S, Bonifacio M. Castagnetti F, et al. Among authors: scappini b. Target Oncol. 2021 Nov;16(6):823-838. doi: 10.1007/s11523-021-00831-4. Epub 2021 Oct 18. Target Oncol. 2021. PMID: 34661826 Free PMC article.
46 results